Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference
Marker Therapeutics, Inc. (MRKR)
Last marker therapeutics, inc. earnings: 11/12 04:01 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a panel discussion at Canaccord Genuity’s Horizons in Oncology Virtual Conference. Dr. Vera will join company executives and key opinion leaders to discuss innovations in T cell-based immunotherapies as part of a panel focused on the future of CAR-T and other novel approaches in solid tumors. Panel Participation Details: EventCG Horizons in Oncology Virtual ConferencePanel TitleCAR-T in Solid Tumors and New T-cell Approaches – Breakthroughs Ahead?DateMonday, April 7, 2025Time11:00 AM – 11:50 AM ET Marker Therapeutics is advancing a unique multi antigen recognizing (MAR)-T cell therapy platform designed to target multiple tumor-associat
Show less
Read more
Impact Snapshot
Event Time:
MRKR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRKR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRKR alerts
High impacting Marker Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MRKR
News
- Marker Therapeutics (NASDAQ:MRKR) had its "sell (e+)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Marker Therapeutics (NASDAQ:MRKR) was upgraded by analysts at HC Wainwright to a "strong-buy" rating.MarketBeat
- Marker Therapeutics (NASDAQ:MRKR) had its "buy" rating reaffirmed by analysts at UBS Group AG.MarketBeat
- Marker Therapeutics (NASDAQ:MRKR) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock.MarketBeat
- Marker Therapeutics (NASDAQ:MRKR) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MRKR&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StrMarketBeat
MRKR
Sec Filings
- 11/19/25 - Form 4
- 11/19/25 - Form 4
- 11/19/25 - Form 4
- MRKR's page on the SEC website